Biblioteca
Alertas Bibliográficas
DIABETES
Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings.
Shaw JL, Bannuru RR, Beach L et al.
Diabetes Care. 2024.
https://doi.org/10.2337/dci24-0073
De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial (TRANSITION‐T2D).
Rodriguez P, Breslaw N, Xiao H et al.
Diabetes Obes Metab. 2024.
https://doi.org/10.1111/dom.16057
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke F, Horn P, Wai-Sun Wong V et al.
J Hepatol. 2024 Sep;81(3):492-542.
https://doi.org/10.1016/j.jhep.2024.04.031
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring.
Tienstra M, de Boer JW, van Doesum JA et al.
Endocr Pract. 2024.
https://doi.org/10.1016/j.eprac.2024.09.013
Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis.
Lewis SJ, Williams CL, Mortimer GL et al.
Diabet Med. 2024.
https://doi.org/doi:10.1111/dme.15394
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ.
Diabetes Care. 2024 Jun 6:dci240003.
doi:10.2337/dci24-0003
ENDOCRINOLOGÍA
Genomic Considerations in the Treatment of Thyroid Carcinoma.
Hattum CJ, Elsey RJ, Meissner T, Spanos WC.
JCO Oncol Pract. 2024;20(7):873-875.
https://www.doi.org/10.1200/OP.24.00198
Polycystic ovary syndrome
Stener-Victorin E, Teede H, Norman RJ, et al. P
Nat Rev Dis Primers. 2024 Apr 18;10(1):27.
https://www.doi.org/10.1038/s41572-024-00511-3
Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol.
Lanzolla G, Marinò M, Menconi F.
Published online July 22, 2024.
doi:10.1038/s41574-024-01016-5
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed MediatorsMulders MCF, de Herder WW, Hofland J.Endocr Rev. 2024 May 7;45(3):351-360.
doi: 10.1210/endrev/bnad035
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Mullen N, Curneen J, Donlon PT, et al.
Endocr Rev. 2024 Jan 4;45(1):125-170.
doi: 10.1210/endrev/bnad026
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
Kyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
N Engl J Med. 2024 Jun 2.
doi: 10.1056/NEJMoa2404655
PEDIATRÍA
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al.
N Engl J Med. 2019 Aug 15;381(7):637-646.
http://doi.org/10.1056/NEJMoa1903822
Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?
Corica D, Aversa T, Ruggeri RM, Cristani M, Alibrandi A, et al.
Front Endocrinol (Lausanne). 2019 Jun 28;10:426.
http://doi.org/10.3389/fendo.2019.00426
Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Goedegebuure WJ, Hokken-Koelega ACS.
Horm Res Paediatr. 2019 Aug 7:1-5.
http://doi.org/10.1159/000501746
Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome.
Singh P, Mahmoud R, Gold JA, Miller JL, Roof E, Tamura R, et al.
J Med Genet. 2018 May 18. pii: jmedgenet-2017-105118.
http://doi.org/10.1136/jmedgenet-2017-105118
Neonatal Features of the Prader-Willi Syndrome; The Case for Making the Diagnosis During the First Week of Life.
Çizmecioğlu FM, Jones JH, Paterson WF, Kherra S, Kourime M, McGowan R, et al.
J Clin Res Pediatr Endocrinol. 2018 Jul 31;10(3):264-273.
http://doi.org/10.4274/jcrpe.0029
Growth hormone – past, present and future.
Ranke MB, Wit JM.
Nat Rev Endocrinol. 2018 May;14(5):285-300
http://doi.org/10.1038/nrendo.2018.22
CIENCIAS BÁSICAS
Genetic testing for indeterminate thyroid cytology: review and meta-analysis.
Vargas-Salas S, Martínez JR, Urra S, Domínguez JM, Mena N, Uslar T, Lagos M, Henríquez M, González HE.
Endocr Relat Cancer. 2018 Mar; 25(3):R163-R177.
DOI: http://doi.org/10.1530/ERC-17-0405
Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
Urra S, Fischer MC, Martínez JR, Véliz L, Orellana P, Solar A, Bohmwald K, Kalergis A, Riedel C, Corvalán AH, Roa JC, Fuentealba R, Cáceres CJ, López-Lastra M, León A, Droppelmann N, González HE.
Oncotarget. 2017 Dec 20; 9(2):2445-2467.
DOI: http://doi.org/10.18632/oncotarget.23502
11β-hydroxysteroid dehydrogenase-1 deficiency alters the gut microbiome response to Western diet.
Johnson JS, Opiyo MN, Thomson M, Gharbi K, Seckl JR, Heger A, Chapman KE.
J Endocrinol. 2017 Feb;232(2):273-283. Epub 2016 Nov 24. PMID:27885053
DOI: https://10.1530/JOE-16-0578
Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism.
Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM, Lavery GG.
J Endocrinol. 2016 Jun;229(3):277-86. Epub 2016 Apr 5.
doi: https://10.1530/JOE-16-0011.